Signs of recovery among its customers from the COVID-19 pandemic helped interventional technology developer AngioDynamics to produce a 6.3% increase in revenue in its 2021 fiscal first quarter.
For the period (end-August 31), the company had sales of $70.2 million, up from $66 million in the fiscal first quarter of 2020. However, AngioDynamics reported a net loss of $4.3 million, compared with a net loss of approximately $1.3 million in the same period a year ago.
Looking ahead, AngioDynamics said it expects sales in fiscal 2021 will range between $278 and $284 million, with adjusted earnings per share of $0.00 to $0.05.
